Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Breckenridge

Drug and asset intelligence for Breckenridge with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 8
Catalysts: 3
Stage: Development stage unavailable

Mechanism of action

JAK Inhibitor

Recent signals(8)

RegulatoryAugust 14, 2026

FDA grants approval status for Breckenridge's Tofacitinib Citrate

The FDA has granted an approval status (AP) for Breckenridge's application for Tofacitinib Citrate (ANDA209633).

StrategyAugust 9, 2026

FDA Grants AP Status for Eplerenone ANDA208283 by Breckenridge

The FDA has granted Abbreviated Approval (AP) status for Breckenridge's ANDA for Eplerenone.

RegulatoryJuly 31, 2026

FDA Approves Pomalidomide Supplement by Breckenridge

The FDA has approved a supplemental application for Pomalidomide submitted by Breckenridge.

RegulatoryJuly 26, 2026

FDA Approves Supplemental Application for Milnacipran Hydrochloride

The FDA has approved a supplemental application for Milnacipran Hydrochloride submitted by Breckenridge.

StrategyJuly 23, 2026

FDA Approves Breckenridge's Tofacitinib Citrate Application

The FDA has approved Breckenridge's application for Tofacitinib Citrate under ANDA209633.

StrategyJuly 19, 2026

Breckenridge's Eplerenone ANDA208283 Receives Abbreviated Approval

Breckenridge's abbreviated new drug application for Eplerenone has received approval from the FDA.

RegulatoryJuly 6, 2026

FDA Acceptance of POMALIDOMIDE Supplement by Breckenridge

The FDA has accepted the supplemental application for POMALIDOMIDE submitted by Breckenridge.

RegulatoryJuly 3, 2026

Breckenridge's Milnacipran Hydrochloride ANDA205071 Receives AP Status

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status to Breckenridge for Milnacipran Hydrochloride.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

— Breckenridge

July 19, 2026 · N/A

Topline Data

— Breckenridge

July 6, 2026 · N/A

Topline Data

— Breckenridge

July 3, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Aldosterone Antagonist →

Antidepressant →

Cardiovascular →

Cardiovascular · Aldosterone Antagonist →

Immunomodulator →

JAK Inhibitor →

Neurology · Antidepressant →

Oncology · Immunomodulator →

Pain Management →

Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.